Jing Zou1, Fei Yue2, Wenjiao Li2, Kun Song2, Xianhan Jiang2, Jinglin Yi3, Leyuan Liu2. 1. Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas, United States of America; Jiangxi Research Institute of Ophthalmology and Visual Sciences, The Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China. 2. Center for Cancer and Stem Cell Biology, Institute of Biosciences and Technology, Texas A&M Health Science Center, Houston, Texas, United States of America. 3. Jiangxi Research Institute of Ophthalmology and Visual Sciences, The Affiliated Eye Hospital of Nanchang University, Nanchang, Jiangxi, China.
Abstract
Autophagy plays an important role in tumorigenesis. Mitochondrion-associated protein LRPPRC interacts with MAP1S that interacts with LC3 and bridges autophagy components with microtubules and mitochondria to affect autophagy flux. Dysfunction of LRPPRC and MAP1S is associated with poor survival of ovarian cancer patients. Furthermore, elevated levels of LRPPRC predict shorter overall survival in patients with prostate adenocarcinomas or gastric cancer. To understand the role of LRPPRC in tumor development, previously we reported that LRPPRC forms a ternary complex with Beclin 1 and Bcl-2 to inhibit autophagy. Here we further show that LRPPRC maintains the stability of Parkin that mono-ubiquitinates Bcl-2 to increase Bcl-2 stability to inhibit autophagy. Under mitophagy stress, Parkin translocates to mitochondria to cause rupture of outer mitochondrial membrane and bind with exposed LRPPRC. Consequently, LRPPRC and Parkin help mitochondria being engulfed in autophagosomes to be degraded. In cells under long-term mitophagy stress, both LRPPRC and Parkin become depleted coincident with disappearance of mitochondria and final autophagy inactivation due to depletion of ATG5-ATG12 conjugates. LRPPRC functions as a checkpoint protein that prevents mitochondria from autophagy degradation and impact tumorigenesis.
Autophagy plays an important role in tumorigenesis. Mitochondrion-associated protein LRPPRC interacts with MAP1S that interacts with LC3 and bridges autophagy components with microtubules and mitochondria to affect autophagy flux. Dysfunction of LRPPRC and MAP1S is associated with poor survival of ovarian cancerpatients. Furthermore, elevated levels of LRPPRC predict shorter overall survival in patients with prostate adenocarcinomas or gastric cancer. To understand the role of LRPPRC in tumor development, previously we reported that LRPPRC forms a ternary complex with Beclin 1 and Bcl-2 to inhibit autophagy. Here we further show that LRPPRC maintains the stability of Parkin that mono-ubiquitinates Bcl-2 to increase Bcl-2 stability to inhibit autophagy. Under mitophagy stress, Parkin translocates to mitochondria to cause rupture of outer mitochondrial membrane and bind with exposed LRPPRC. Consequently, LRPPRC and Parkin help mitochondria being engulfed in autophagosomes to be degraded. In cells under long-term mitophagy stress, both LRPPRC and Parkin become depleted coincident with disappearance of mitochondria and final autophagy inactivation due to depletion of ATG5-ATG12 conjugates. LRPPRC functions as a checkpoint protein that prevents mitochondria from autophagy degradation and impact tumorigenesis.
Autophagy, or self-digestion, is a process that begins with the formation of isolation membranes that engulf substrates including dysfunctional organelles, mis-folded/aggregated proteins and/or other macromolecules to form autophagosomes [1], [2]. Then autophagosomes fuse with lysosomes to generate autolysosomes in which substrates are degraded [3]. Mitochondrion is one of the most prominent and vital type of organelles in eukaryotic cells. During cell cycling, mitochondria are constantly synthesized, used, damaged and destroyed through autophagy (here referred to as mitophagy) [4], [5]. Parkin, whose mutations may be counted for Parkinson's disease in small numbers of patients, has recently been found to regulate the turnover of mitochondria through mitophagy [6], [7]. The role of autophagy in cancer development has attracted great attention but is not well understood [8].LRPPRC is an interactive protein of MAP1S, a mitochondria and microtubule-associated protein previously named as C19ORF5 [9]–[11]. It was suggested that mutations in the LRPPRC gene cause Leigh syndrome, French-Canadian type (LSFC), a human disorder characterized with neurodegeneration and cytochrome c oxidase deficiency [12]. Based on the somatic mutation data of 17301 genes from 316 ovarian cancerpatients from The Cancer Genome Atlas, mutations in both LRPPRC and MAP1S were found to reduce the survival of patients [13]. As a sequence homologue of the microtubule-associated proteinMAP1A and MAP1B, MAP1S similarly interacts with mammalian autophagy marker LC3 [14]–[16] and bridges autophagic components with microtubules and mitochondria to affect autophagosomal biogenesis and degradation and suppress genome instability and tumorigenesis [16]–[18]. Recently, we found that elevated levels of LRPPRC in prostate adenocarcinomas are closely associated with poor prognosis of prostate cancerpatients [19]. A similar trend was independently reported in patients with gastric cancer [20].To better understand the role of LRPPRC in cancer development, we have previously reported that LRPPRC associates with mitochondria, interacts with Beclin 1 and Bcl-2 and form a ternary complex to maintain the Bcl-2 stability. Suppression of LRPPRC leads to Bcl-2 degradation that leads to release of more Beclin 1 to form complexes with PI3KCIII to activate basal levels of autophagy upstream of the ATG5-ATG12 conjugates-mediated LC3-I to LC3-II conversion [21]. Since inner mitochondrial membrane-associated LRPPRC [22] was suggested to interact with mitophagy initiator Parkin based on Mass Spectrometry analyses from different labs [23], [24] and its suppression led to enhancement of autophagy degradation of mitochondria in lysosomes [21], we are triggered to investigate the specific role of LRPPRC in mitophagy in addition to its general role in the regulation of basal levels of autophagy.In this study, we show that LRPPRC interacts with Parkin and maintains the stability of Parkin that stabilizes Bcl-2 to suppress autophagy from initiation. Under mitophagy stress, mitophagy initiator Parkin translocates to depolarized mitochondria to bind with LRPPRC. Consequently, LRPPRC and Parkin regulate VADC1, Drp1 and Mitofusin 1 to initiate autophagy and mitophagy, and eventually become depleted along their associated mitochondria in cells under long-term mitophagy stress. Therefore, LRPPRC protects mitochondria from autophagy degradation.
Materials and Methods
Antibodies, siRNAs, plasmids, and other reagents
Antibody against LRPPRC (1B8) was a gift from Dr. Serafín Piñol-Roma, The Sophie Davis School of Biomedical Education, the City College of New York, New York [22]. Antibodies against humanLC3 (NB 100-2331) were purchased from Novus Biologicals and A&G Pharmaceutical, Inc.. The IgG control antibodies from mouse (SC-2025) and rabbit (SC-2027), primary antibodies against β-actin (SC-47778), LRPPRC (mouse, SC166178; rabbit, SC-66845), ATG5 (SC-33210), Bcl-2 (SC-7832), p27 (SC-776), Beclin 1 (SC-11427), Mitofusin 1 (SC-166644), Drp1 (SC-32898), VDAC1 (SC-98708), and GFP (SC-8334), and siRNA molecules specific to LRPPRC (sc-44734), Parkin (SC-42158) and random sequence control (sc-44234) were from Santa Cruz Biotechnology, Inc.. Antibodies against Parkin (mouse, ab77924; rabbit, ab15954), Pink1 (ab23707) and LAMP2 (ab18528) were from abcam. Antibody against P62 (SQSTN1, BWL-PW9860) was from Enzo Life Sciences International Inc. Antibody against Tom20 (612278) was from BD Transduction Laboratories. HRP-conjugated secondary antibodies against mouse (#172-1011) and rabbit (#172-1019) were from Bio-Rad. Rhodamine Red-Xgoat anti-mouse IgG and Alexa Fluor 633goat anti-rabbit IgG (R6393 and A-21070), MitoTracker Red CMXRos, Lipofectamine 2000 (11668-027) and Oligofectamine (12252-011) were from Invitrogen. GFP-LC3 [25] and GFP-Parkin [26] were supplied by Drs. Mizushima and Youle, respectively. MG-132, Bafilomycin A1, Carbonyl cyanide m-chlorophenyl hydrazone (CCCP) and 6-hydroxydopamine (6-OHDA) were from Sigma. The protein G beads were from Amersham Biosciences.
Cell transfection and co-immunoprecipitation assay
HeLa cells or HeLa cells stably expressing EGFP-LC3 that was established as previously described [4], [25] were transfected with siRNA molecules packed with Oligofectamine and/or GFP-Parkin plasmid [25] packed in Lipofectamine 2000 as we previously described [4], [27]. In order to suppress LRPPRC and overexpress GFP or GFP-Parkin simultaneously, cell densities were increased to 50–60% confluence to reduce transfection-induced cell death. Cell lysates were prepared from attached cells and coimmunoprecipitation were performed as previously described [28]. Same amount of cell lysates were subjected to immunoprecipitation with equal amounts of specific antibodies and control antibodies (IgG) from the same species.
Fluorescent microscopy and transmission electron microscopy
Immunofluorescent stain and mitochondria tracking were performed and images were captured with the laser scanning microscope similarly as described [4], [25]. HeLa cells grown in 6-well culture plates were transfected with LRPPRC-specific siRNA or treated with CCCP in the absence or presence of lysosomal inhibitor Bafilomycin A1, and then fixed and processed for examination with a JEM 1010 transmission electron microscope (JEOL, USA, Inc.) as described [16]. Percentages of areas occupied by autophagic vacuoles or mitochondria were measured using the ImageJ program.
Results
Long-term mitophagy stress leads to depletion of LRPPRC and mitochondria and impairment of autophagy/mitophagy flux
LRPPRC suppresses the initiation of basal levels of autophagy and mitophagy via enhancing the stability of Bcl-2 protein [21]. Since LRPPRC is a mitochondrion-associated protein, we were interested to investigate its role in mitophagy, autophagy for turnover of mitochondria. As widely done in literatures [29], we used carbonyl cyanide 3-chlorophenylhydrazone (CCCP), a chemical causing uncoupling of mitochondrial potential, to induce mitophagy. We found that short-term CCCP treatment (20 µM for 6–12 hrs) did not change the levels of LRPPRC and Parkin but increased levels of ATG5-ATG12 conjugates, LC3-II and protein aggresomal marker P62 in 293T cells treated with lysosomal inhibitor Bafilomycin A1, suggesting that autophagy flux was elevated (Figure 1A). More swollen mitochondria were observed in cells that received CCCP treatment for 6 hrs than in untreated cells in the absence of Bafilomycin A1 and much higher mitochondria mass as reflected by the Tom20 levels remained in cells received CCCP treatment for 12 hrs than in untreated cells in the presence of Bafilomycin A1 (Figure 1A–C), suggesting that initial induction of mitophagy with CCCP may activate mitophagy. Since inhibition of lysosomal activity with Bafilomycin A1 was confirmed to have no impact on LRPPRC levels,[21] it is the long-term CCCP treatment that eventually led to depletion of LRPPRC and Bcl-2 but did not alter levels of Beclin 1 and P27 levels (Figure 1A), supposing to cause autophagy activation as we previously reported [16], [21]. However, the levels of ATG5-ATG12 conjugates were gradually reduced with prolonged period of CCCP treatment (Figure 1A). Activation of autophagy mediated by LRPPRC depletion occurs prior to ATG5-ATG12-mediated LC3-I to LC3-II conversion [21]. Similar to the situation as shown in the LRPPRC and ATG5 double knockdown experiments [21], LC3-II and P62 levels decreased in the absence or presence of Bafilomycin A1 48 hrs after CCCP exposure (Figure 1A), indicating an impairment of autophagy flux. Long-term CCCP treatment eventually led to depletion of mitochondrial mass as indicated by Tom20 levels in immunoblot and mitochondria-occupied area under electron microscopy, and mitophagy initiator Parkin (Figure 1A–C). Therefore, CCCP treatment initially led to activation of autophagy machinery and long-term CCCP insults led to depletion of mitochondria and the associated LRPPRC, and eventually caused impairment of autophagy flux.
Figure 1
Long-term mitophagy stress results in depletion of LRPPRC and mitochondria and impairment of autophagy flux.
(A) Immunoblot analysis of lysates from 293T cells treated with 10 µM carbonyl cyanide 3-chlorophenylhydrazone (CCCP) for different lengths of time (hrs) in the absence (Ctrl) or presence of lysosomal inhibitor Bafilomycin A1 (BAF, 10 µM) for 6 hrs before harvest. No Bafilomycin A1 was added in two treatments at time zero. (B) Representative TEM imaging of cells as treated in panel (A). No Bafilomycin A1 was added in two treatments at time zero. Bar = 500 nm. (C) Percentages of area occupied by mitochondria in the TEM images. Data were the average and standard deviation of at least three repeats and the differences are compared based on Student T-test. *, p value ≤0.05. **, p value ≤0.01. (D,E) Immunoblot analyses of lysates from 293T cells untreated (None) or treated with 100 µM 6-hydroxydopamine (6-OHDA) for different time (hrs) in the absence or presence of Bafilomycin A1 for 0–6 hrs (D) or 6 hrs before harvest (E).
Long-term mitophagy stress results in depletion of LRPPRC and mitochondria and impairment of autophagy flux.
(A) Immunoblot analysis of lysates from 293T cells treated with 10 µM carbonyl cyanide 3-chlorophenylhydrazone (CCCP) for different lengths of time (hrs) in the absence (Ctrl) or presence of lysosomal inhibitor Bafilomycin A1 (BAF, 10 µM) for 6 hrs before harvest. No Bafilomycin A1 was added in two treatments at time zero. (B) Representative TEM imaging of cells as treated in panel (A). No Bafilomycin A1 was added in two treatments at time zero. Bar = 500 nm. (C) Percentages of area occupied by mitochondria in the TEM images. Data were the average and standard deviation of at least three repeats and the differences are compared based on Student T-test. *, p value ≤0.05. **, p value ≤0.01. (D,E) Immunoblot analyses of lysates from 293T cells untreated (None) or treated with 100 µM 6-hydroxydopamine (6-OHDA) for different time (hrs) in the absence or presence of Bafilomycin A1 for 0–6 hrs (D) or 6 hrs before harvest (E).Similarly, we treated 293T cells with 6-hydroxydopamine (6-OHDA), an oxidative toxin to generate experimental models of Parkinson's disease that is non-enzymatically oxidized to produce reactive oxygen species such as hydrogen peroxide to induce mitophagy [30]. We found that 6-OHDA behaved similar to CCCP but with accelerated pace, activated autophagy flux at early stage (Figure 1D) and resulted in reduction of Tom20-indictaed mitochondria mass and the mitochondrion-associated LRPPRC at late stage (Figure 1E). The fact that two drugs inducing mitophagy in different mechanisms have the same impact on LRPPRC levels and activities of autophagy and mitophagy suggests that LRPPRC plays a general role in mitophagy.
LRPPRC interacts with mitophagy stress-induced mitochondrion-translocated mitophagy initiator Parkin
Parkin and Pink1 were previously suggested to interact with LRPPRC as detected by Mass Spectrometry [23], [24], [31]. To understand the role of LRPPRC in mitophagy, we tested the interaction of LRPPRC with Parkin or Pink1. Co-immunoprecipitation of endogenous proteins revealed that LRPPRC interacted with Parkin but not with Pink 1 (Figure 2A). Upon CCCP treatment for 3 hrs to induce mitophagy in 293T cells, more endogenous Parkin proteins were precipitated with similar amount of immunoprecipitated LRPPRC, or more endogenous LRPPRC proteins were precipitated with less immunoprecipitated Parkin (Figure 2B–D). When HeLa cells transiently expressing GFP-Parkin were induced to commit mitophagy with CCCP for 3 hrs, the diffusing GFP-Parkin translocated to and colocalized with the mitochondrion-associated LRPPRC (Figure 2E). The short-term CCCP treatment did not change the levels of LRPPRC but dramatically increased the amount of LRPPRC-bound GFP-Parkin (Figure 2F–G). Thus, Parkin translocates to mitochondrion to induce rupture of outer mitochondrial membrane [32] and bind with the exposed inner mitochondrial membrane-associated LRPPRC under mitophagy stress.
Figure 2
LRPPRC interacts with mitophagy stress-induced mitochondrion-translocated mitophagy initiator Parkin.
(A) Immunoblot analyses of interaction between LRPPRC and Parkin or Pink 1. Same amount of 293T cell lysates were used to perform immunoprecipitation with same amount of anti-LRPPRC antibody or mouse IgG control under identical procedure. (B–D) Coimmunoprecipitation analyses of LRPPRC-Parkin interaction under mitophagy stress. Lysates with equal amount of total proteins prepared from 293T cells untreated or similarly treated with 10 µM CCCP for 2.5 hrs were immunoprecipitated with anti-LRPPRC or Parkin antibody (B). IgG served as control antibody. The relative amounts of Parkin bound on LRPPRC (C) or LRPPRC bound on Parkin (D) were quantified against the precipitated amounts of LRPPRC (C) or Parkin (D). The level in the absence of CCCP is set to 1. **, p value ≤0.01. (E) A fluorescent imaging analysis showing the colocalization of LRPPRC with GFP-Parkin. CCCP, HeLa cells transiently expressing GFP-Parkin for 48 hrs were treated with 10 µM CCCP for 2.5 hrs before fixation. Bottom panel is the amplification of the square in the middle panel. Bar = 10 µm. (F,G) Coimmunoprecipitation analyses of LRPPRC-Parkin interaction in HeLa cells overexpressing GFP-Parkin untreated or similarly treated with CCCP as shown in (E). GFP-Parkin is coimmunoprecipitated with anti-LRPPRC antibody (F), and the relative amounts of GFP-Parkin bound on LRPPRC are quantified against the precipitated amounts of LRPPRC (G). The level in the absence of CCCP is set to 1. **, p value ≤0.01. (H,I) Fluorescent imaging analyses showing the colocalization of GFP-Parkin and LRPPRC with RFP-LC3 punctate foci (H) or LAMP2-labelled lysosomes (I) 3 or 12 hrs after exposure to CCCP in the absence (Ctrl) or presence of Bafilomycin A1 (BAF). Bar = 5 µm in (H) and 2 µm in (I).
LRPPRC interacts with mitophagy stress-induced mitochondrion-translocated mitophagy initiator Parkin.
(A) Immunoblot analyses of interaction between LRPPRC and Parkin or Pink 1. Same amount of 293T cell lysates were used to perform immunoprecipitation with same amount of anti-LRPPRC antibody or mouse IgG control under identical procedure. (B–D) Coimmunoprecipitation analyses of LRPPRC-Parkin interaction under mitophagy stress. Lysates with equal amount of total proteins prepared from 293T cells untreated or similarly treated with 10 µM CCCP for 2.5 hrs were immunoprecipitated with anti-LRPPRC or Parkin antibody (B). IgG served as control antibody. The relative amounts of Parkin bound on LRPPRC (C) or LRPPRC bound on Parkin (D) were quantified against the precipitated amounts of LRPPRC (C) or Parkin (D). The level in the absence of CCCP is set to 1. **, p value ≤0.01. (E) A fluorescent imaging analysis showing the colocalization of LRPPRC with GFP-Parkin. CCCP, HeLa cells transiently expressing GFP-Parkin for 48 hrs were treated with 10 µM CCCP for 2.5 hrs before fixation. Bottom panel is the amplification of the square in the middle panel. Bar = 10 µm. (F,G) Coimmunoprecipitation analyses of LRPPRC-Parkin interaction in HeLa cells overexpressing GFP-Parkin untreated or similarly treated with CCCP as shown in (E). GFP-Parkin is coimmunoprecipitated with anti-LRPPRC antibody (F), and the relative amounts of GFP-Parkin bound on LRPPRC are quantified against the precipitated amounts of LRPPRC (G). The level in the absence of CCCP is set to 1. **, p value ≤0.01. (H,I) Fluorescent imaging analyses showing the colocalization of GFP-Parkin and LRPPRC with RFP-LC3 punctate foci (H) or LAMP2-labelled lysosomes (I) 3 or 12 hrs after exposure to CCCP in the absence (Ctrl) or presence of Bafilomycin A1 (BAF). Bar = 5 µm in (H) and 2 µm in (I).
Both LRPPRC and Parkin are co-localized with LC3 punctate foci and LAMP2-labelled lysosomes under mitophagy stress
When HeLa cells stably expressing RFP-LC3 and transiently expressing GFP-Parkin were exposure to CCCP for 3 hrs, we found that both LRPPRC and Parkin were not obviously colocalized with RFP-LC3 punctate foci even in the presence of Bafilomycin A1 (Figure 2H), suggesting the damaged parkin and LRPPRC-associated mitochondria were aggregated but not packaged into LC3-associated autophagosomes yet. After 12 hrs exposure to CCCP, colocalization of LRPPRC and Parkin-associated mitochondria with RFP-LC3 punctate foci were detected in the absence but became obvious in the presence of Bafilomycin A1 (Figure 2H, white in merge), indicating the damaged parkin and LRPPRC-associated mitochondria were packaged into LC3-associated autophagosomes for effective turnover. This was further confirmed by the colocalization of Parkin and LRPPRC-associated mitochondria with LAMP2-labelled lysosomes (Figure 2I).
Under mitophagy stress, translocation of Parkin to LRPPRC-associated mitochondria induces mitochondrial aggregation and consequently degradation of LRPPRC, Parkin and mitochondria
To understand mutual impact of LRPPRC and Parkin during mitophagy process, we examined their distribution on mitochondria at different times after exposure to CCCP (Figure 3). LRPPRC associated with Tom20-labelled mitochondria and overexpressed GFP-Parkin diffused in cytosol of untreated normal HeLa cells. GFP-Parkin translocated to LRPPRC-associated mitochondria and induced mitochondrial aggregation at 3 hrs after CCCP treatment. Mitochondrial aggregates gradually disappeared with prolonged periods of CCCP treatment from 6 to 24 hrs. A lot of GFP-Parkin-associated and Tom20-labelled mitochondrial fragments containing no LRPPRC (yellow foci in the merge panel) existed at 6 to 24 hrs after CCCP exposure. Finally, mitochondria and the associated LRPPRC and Parkin were depleted in cells after 48 hrs CCCP treatment.
Figure 3
Colocalization among LRPPRC, Parkin and Tom20-indicated mitochondria at different times under mitophagy stress.
HeLa cells transiently expressing GFP-Parkin treated with 10 µM CCCP for different times were fixed and stained with antibodies against LRPPRC (blue) and Tom20 (red). Mitochondrial aggregates carrying both LRPPRC and Parkin signals were shown as white in the Merge panels. Bar = 10 µm.
Colocalization among LRPPRC, Parkin and Tom20-indicated mitochondria at different times under mitophagy stress.
HeLa cells transiently expressing GFP-Parkin treated with 10 µM CCCP for different times were fixed and stained with antibodies against LRPPRC (blue) and Tom20 (red). Mitochondrial aggregates carrying both LRPPRC and Parkin signals were shown as white in the Merge panels. Bar = 10 µm.Similar to as shown in Figure 2H, most of mitochondria were associated with Parkin and Parkin-associated mitochondria were not found to be colocalized with RFP-LC3 punctate foci or LAMP2-labelled lysosomes in in early time after CCCP exposure in the absence of Bafilomycin A1 (Figure 4,5). Those mitochondria were effectively packaged into autophagosomes but not effectively degraded through lysosomes so that we were able to observe some mitochondria-containing autophagosomes accumulated at 12 hrs after exposure (Figure 5). Those mitochondria free of LRPPRC but associating with Parkin were not colocalized with RFP-LC3 punctate foci or LAMP2-labelled lysosomes at 24 hrs after exposure (Figure 4,5), indicating a positive role of LRPPRC for mitochondria to be packaged into autophagosomes. Finally, mitochondria disappeared 48 hrs after exposure (Figure 4,5).
Figure 4
Colocalization among Parkin, Tom20-indicated mitochondria and RFP-LC3-labelled autophagosomes at different times under mitophagy stress.
HeLa cells stably expressing RFP-LC3 transiently expressed GFP-Parkin treated with 10 µM CCCP for different times were fixed and stained with antibodies against Tom20 (blue). Mitochondrial aggregates associating with Parkin signals were shown as cyan in the Merge panels. Bar = 5 µm.
Figure 5
Colocalization among Parkin, Tom20-indicated mitochondria and LAMP2-labelled lysosomes at different times under mitophagy stress.
HeLa cells transiently expressing GFP-Parkin treated with 10 µM CCCP for different times were fixed and stained with antibodies against LAMP2 (red) and Tom20 (blue). Lysosome-contained Parkin-associated mitochondrial aggregates were shown as white in the Merge panels. All experiments were carried out in the absence of lysosomal inhibitor. Bar = 2 µm.
Colocalization among Parkin, Tom20-indicated mitochondria and RFP-LC3-labelled autophagosomes at different times under mitophagy stress.
HeLa cells stably expressing RFP-LC3 transiently expressed GFP-Parkin treated with 10 µM CCCP for different times were fixed and stained with antibodies against Tom20 (blue). Mitochondrial aggregates associating with Parkin signals were shown as cyan in the Merge panels. Bar = 5 µm.
Colocalization among Parkin, Tom20-indicated mitochondria and LAMP2-labelled lysosomes at different times under mitophagy stress.
HeLa cells transiently expressing GFP-Parkin treated with 10 µM CCCP for different times were fixed and stained with antibodies against LAMP2 (red) and Tom20 (blue). Lysosome-contained Parkin-associated mitochondrial aggregates were shown as white in the Merge panels. All experiments were carried out in the absence of lysosomal inhibitor. Bar = 2 µm.
LRPPRC and Parkin mutually regulate stability of each other
To understand the relation between LRPPRC and Parkin, we first changed the levels of Parkin by transfection with a Parkin-specific siRNA in 293T cells or a plasmid expressing GFP-Parkin in HeLa cells. Either suppression or overexpression of Parkin caused no change in LRPPRC levels (Figure 6A–D), suggesting Parkin did not have impact on the levels of LRPPRC under normal condition. When HeLa cells overexpressing Parkin were treated with CCCP, LRPPRC was destabilized and mitophagy was enhanced because of decrease of Tom20 levels (Figure 6E–G). Suppression of LRPPRC with LRPPRC-specific siRNA in 293T cells led to significant decrease of both LRPPRC and Parkin levels (Figure 6H–J). Overexpression of GFP-LRPPRC increased the half-life of Parkin from about 6 hrs to more than 24 hrs and dramatically enhanced the stability of LRPPRC (Figure 6K,L). Therefore, LRPPRC maintained the stability of Parkin and mitochondrial translocation of Parkin under mitophagy stress led to subsequent degradation of both LRPPRC and Parkin.
Figure 6
LRPPRC controls the stability of Parkin.
(A–D) Immunoblot analyses showing the impact of different levels of Parkin on the levels of LRPPRC. Equal amount of cell lysates from 293T cells treated with random (Mock) or Parkin-specific siRNA (A) or HeLa cells overexpressing GFP or GFP-Parkin (C) were analyzed by immunoblot and LRPPRC levels under different conditions were quantified (B,D). n.s., not significant. (E) Immunoblot analyses showing the impact of different levels of Parkin on the levels of LRPPRC under mitophagy stress. Equal amount of cell lysates from HeLa cells overexpressing GFP or GFP-Parkin treated with CCCP for different times were analyzed by immunoblot. (F,G) Plots of relative intensities of LRPPRC (E) or Tom20 (F) in HeLa cells treated as in (E). The intensities in samples at time zero were set to 1. (H) An immunoblot analysis showing that suppression of LRPPRC resulted in degradation of Parkin. 293T cells were treated with Mock or LRPPRC siRNA for 72 hrs. Equal amount of lysates were analyzed. (I,J) Plots of relative intensities of LRPPRC (I) or Parkin (J) in 293T cells treated with Mock or LRPPRC siRNA. The intensities in samples treated with MOCK siRNA were set to 1. Data were the average and standard deviation of at least three repeats and the differences were compared based on paired T-test. *, p value ≤0.05; ***, p value ≤0.0001. (K) Immunoblot analyses showing that overexpression of LRPPRC enhanced the stability of Parkin. COS7 cells were transiently transfected with plasmids carry only GFP or GFP-LRPPRC for 24 hrs, detached and distributed equally to 8 wells. Each well was treated with cycloheximide (CHX) for different times (hrs). Equal amount of lysates as indicated by total protein concentration and β-actin control were analyzed. (L) Plots of relative intensities of Parkin in COS7 cells treated as in (K). The intensities in samples at time zero were set to 1.
LRPPRC controls the stability of Parkin.
(A–D) Immunoblot analyses showing the impact of different levels of Parkin on the levels of LRPPRC. Equal amount of cell lysates from 293T cells treated with random (Mock) or Parkin-specific siRNA (A) or HeLa cells overexpressing GFP or GFP-Parkin (C) were analyzed by immunoblot and LRPPRC levels under different conditions were quantified (B,D). n.s., not significant. (E) Immunoblot analyses showing the impact of different levels of Parkin on the levels of LRPPRC under mitophagy stress. Equal amount of cell lysates from HeLa cells overexpressing GFP or GFP-Parkin treated with CCCP for different times were analyzed by immunoblot. (F,G) Plots of relative intensities of LRPPRC (E) or Tom20 (F) in HeLa cells treated as in (E). The intensities in samples at time zero were set to 1. (H) An immunoblot analysis showing that suppression of LRPPRC resulted in degradation of Parkin. 293T cells were treated with Mock or LRPPRC siRNA for 72 hrs. Equal amount of lysates were analyzed. (I,J) Plots of relative intensities of LRPPRC (I) or Parkin (J) in 293T cells treated with Mock or LRPPRC siRNA. The intensities in samples treated with MOCK siRNA were set to 1. Data were the average and standard deviation of at least three repeats and the differences were compared based on paired T-test. *, p value ≤0.05; ***, p value ≤0.0001. (K) Immunoblot analyses showing that overexpression of LRPPRC enhanced the stability of Parkin. COS7 cells were transiently transfected with plasmids carry only GFP or GFP-LRPPRC for 24 hrs, detached and distributed equally to 8 wells. Each well was treated with cycloheximide (CHX) for different times (hrs). Equal amount of lysates as indicated by total protein concentration and β-actin control were analyzed. (L) Plots of relative intensities of Parkin in COS7 cells treated as in (K). The intensities in samples at time zero were set to 1.
LRPPRC suppresses autophagy/mitophagy through controlling the Parkin stability
As an E3 ubiquitin ligase, Parkin binds with Bcl-2 and mono-ubiquitinates it to enhance its stability [33]. As predicated, overexpression of Parkin led to increases in Bcl-2 levels in cells containing either normal or suppressed levels of LRPPRC and suppression of LRPPRC led to destabilization of Parkin and further decrease of Bcl-2 levels (Figure 7A,B). Consistent with our previous report [21], suppression of LRPPRC led to activation of basal levels of autophagy, and overexpression of Parkin that caused elevation of Bcl-2 levels led to inhibition of basal levels of autophagy as indicated by the reduced levels of LC3-II in the presence of Bafilomycin A1 (Figure 7C,D).
Figure 7
LRPPRC maintains levels of Bcl-2 and suppresses basal levels of autophagy through Parkin.
(A) Immunoblot analyses of Bcl-2 levels in 293T cells overexpressing Parkin in the absence or presence of LRPPRC siRNA. (B) Plots of relative intensities of Bcl-2 as shown in (A). The intensities in samples overexpressing GFP were set to 1. Data were the average and standard deviation of at least three repeats and the differences were compared based on paired T-test. *, p value ≤0.05. (C) Immunoblot analyses of LC3-II levels in 293T cells treated with either random or LRPPRC-specific siRNAs and/or overexpressing GFP or GFP-Parkin in the presence of Bafilomycin A1. (D) Plots of relative intensities of LC3-II as shown in (C). The intensities in samples treated with random siRNA and overexpressing GFP were set to 1. Data were the average and standard deviation of at least three repeats and the differences were compared based on paired T-test. *, p value ≤0.05.
LRPPRC maintains levels of Bcl-2 and suppresses basal levels of autophagy through Parkin.
(A) Immunoblot analyses of Bcl-2 levels in 293T cells overexpressing Parkin in the absence or presence of LRPPRC siRNA. (B) Plots of relative intensities of Bcl-2 as shown in (A). The intensities in samples overexpressing GFP were set to 1. Data were the average and standard deviation of at least three repeats and the differences were compared based on paired T-test. *, p value ≤0.05. (C) Immunoblot analyses of LC3-II levels in 293T cells treated with either random or LRPPRC-specific siRNAs and/or overexpressing GFP or GFP-Parkin in the presence of Bafilomycin A1. (D) Plots of relative intensities of LC3-II as shown in (C). The intensities in samples treated with random siRNA and overexpressing GFP were set to 1. Data were the average and standard deviation of at least three repeats and the differences were compared based on paired T-test. *, p value ≤0.05.Suppression of LRPPRC caused degradation of Parkin and further treatment with CCCP resulted in faster degradation of Parkin (Figure 8A,B). Mitochondria have been suggested to be docked into autophagosomes via the interaction of ubiquitinated membrane proteins with LC3-II-interactive substrate receptor P62. Mitochondria-associated protein Mitofusin 1, Drp1 and VDAC1 have been confirmed as the substrates of Parkin E3 ligase and claimed as the P62-interactive membrane proteins but such claim is still in disputation [7]. When cells with LRPPRC suppressed were exposed to mitophagy inducer CCCP, activated E3 ligase activity of Parkin led to decreases in levels of VDAC1, Drp1 and Mitofusin 1 caused by faster turnover through autophagy (Figure 8A,B).
Figure 8
LRPPRC suppresses mitophagy through controlling the Parkin stability.
(A,B) Immunoblot analyses of impact of LRPPRC on Parkin, Parkin substrate VDAC1, Drp1 and Mitofusion, and autophagy/mitophagy in 293T cells. Lysates with equal amount of total proteins were prepared from cells treated with random (Mock) or LRPPRC-specific siRNA and induced mitophagy with 0 or 10 µM CCCP in the absence or presence of Bafilomysin A1. Same amounts of cell lysates were subjected to immunoblot analyses (A) and the relative protein levels to those of β-Actin were plotted (B). **, p value ≤0.01. (C) Immunoblot analyses of impact of LRPPRC on Parkin and mitophagy in COS7 cells overexpressing GFP or GFP-LRPPRC treated with 10 µM CCCP for different times (hrs). (D,E) Plots of relative intensity of Parkin (D) or Tom20 (E) for immunoblots shown in (C). The intensities in samples collected at 0 hr were adjusted based on β-Actin intensity and set to 1. (F) Immunostaining analysis of mitochondrial mass in COS7 cells similarly treated as in (C) showing the intensities of Tom20-labelled mitochondrial mass. All images were captured under identical protocol of staining and imaging settings.
LRPPRC suppresses mitophagy through controlling the Parkin stability.
(A,B) Immunoblot analyses of impact of LRPPRC on Parkin, Parkin substrate VDAC1, Drp1 and Mitofusion, and autophagy/mitophagy in 293T cells. Lysates with equal amount of total proteins were prepared from cells treated with random (Mock) or LRPPRC-specific siRNA and induced mitophagy with 0 or 10 µM CCCP in the absence or presence of Bafilomysin A1. Same amounts of cell lysates were subjected to immunoblot analyses (A) and the relative protein levels to those of β-Actin were plotted (B). **, p value ≤0.01. (C) Immunoblot analyses of impact of LRPPRC on Parkin and mitophagy in COS7 cells overexpressing GFP or GFP-LRPPRC treated with 10 µM CCCP for different times (hrs). (D,E) Plots of relative intensity of Parkin (D) or Tom20 (E) for immunoblots shown in (C). The intensities in samples collected at 0 hr were adjusted based on β-Actin intensity and set to 1. (F) Immunostaining analysis of mitochondrial mass in COS7 cells similarly treated as in (C) showing the intensities of Tom20-labelled mitochondrial mass. All images were captured under identical protocol of staining and imaging settings.As we previously reported [21], LRPPRC suppression led to autophagy activation as indicated by LC3-II levels in the presence of Bafilomycin A1 (Figure 8A,B). Activated autophagy reduced the levels of Tom20 and enhanced the degradation of TOM20-labelled mitochondria (Figure 8A,B). Prolonged periods of CCCP treatment led to gradual degradation of Parkin and Tom20-labelled mitochondria and overexpression of LRPPRC maintained the stability of Parkin and prevented the degradation of Tom20-labelled mitochondria (Figure 8C–F).
Discussion
The anti-apoptotic proteins of Bcl-2 family exhibit opposite impact on autophagy initiation. Our previous report shows that LRPPRC controls the stability of Bcl-2 to suppress basal levels of autophagy mainly through the Beclin 1-depdendent PI3K-AKT-mTOR pathway [21]. Here we demonstrate that LRPPRC interacts with Parkin and maintains its stability so that the Parkin substrates including Bcl-2 and Parkin itself are stabilized. Thus, LRPPRC protects mitochondria from autophagy degradation. Under mitophagy stress, Parkin translocates to mitochondrion to induce rupture of outer mitochondrial membrane [32] and bind with LRPPRC. Then, LRPPRC, Parkin and other substrates of Parkin may be ubiquitinated by Parkin E3 ligase and recognized by autophagy machinery and guide mitochondria to be degraded through mitophagy.Parkin is selectively recruited to dysfunctional mitochondria with low membrane potential in mammalian cells. After recruitment, Parkin mediates the engulfment of mitochondria by autophagosomes and the selective elimination of impaired mitochondria [34]. Mitofusin 1 [35], Drp1 [36] and VDAC1 [6] were reported to be substrates of Parkin while LRPPRC is also listed as Parkin substrates in the associated online supplementary although the exact mechanism is still in investigation [37]. Ubiquitinated VDAC1 and Drp1 will cause their associated mitochondria to be brought into autophagosomes and autolysosomes for degradation. Since a significant portion of Bcl-2 is associated with mitochondria and Parkin-mono-ubiquitinated Bcl-2 is more stable, suppression of LRPPRC leads to decreases in levels of Parkin and Bcl-2 and activation of basal autophagy as we previous reported [21]. Interestingly, Parkin itself is the substrate of its ligase activity. After auto-ubiquitination, Parkin gradually becomes depleted along Bcl-2 and ATG5-ATG12 conjugate in cells under long-term mitophagy stress.The drug-induced mitophagy stress is an artificially introduced pathological condition. Under normal physiological condition, it is unlikely that all of mitochondria in cells are simultaneously damaged. The drug-induced mitochondrial damages are so massive that autophagy/mitophagy machinery is incapable of handing so many damaged mitochondria immediately. This is possibly the reason that we observed a large amount of mitochondria aggregates accumulated in the first 12 hrs after exposure to mitophagy inducer. These mitochondrial aggregates then become fragmented mitochondria to be engulfed in autophagosomes and further autolysosomes for degradation.Parkinson's disease results from the death of dopamine-containing cells in the substantia nigra region of the midbrain. Several mutations in specific genes such as Parkin have been identified in a few individuals with familial form or autosomal recessive juvenile Parkinson's disease [38]. Mitochondrial dysfunction and oxidative stress have long been implicated as the general pathophysiologic mechanisms underlying Parkinson's disease [39]. Impairment of autophagy and mitophagy processes may be the determining force in the majority of patients to develop Parkinson's disease [39].Interestingly, the same group of proteins involved in juvenile Parkinson's disease also plays important roles in tumorigenesis although the somatic mutations of Parkin identified are homozygous in Parkinson's disease and heterozygous in cancers [40]. If the autophagic process is blocked before autophagosomal formation, the fragmented mitochondria will release cytochrome c and other molecules to induce apoptosis that is usually associated with diverse forms of aggregation and perinuclear clustering of the dysfunctional mitochondria [41], [42]. If either the process is blocked before the autolysosomal formation or autophagosomes are not degraded efficiently, the accumulated mitochondria may become damaged by their own production of superoxide and start to leak electrons and lose their membrane potentials, and even further induce robust oxidative stress [43]. High levels of oxidative stress are lethal in post-mitotic neuronal cells in Parkinson's disease, while sub-lethal levels of oxidative stress not only induces DNA double-strand breaks but also weakens mitotic checkpoint function so that cells carrying damaged genomes can escape mitotic checkpoint to enter next rounds of mitosis to further destabilize the genomes and result in tumorigenesis [16]–[18]. High levels of LRPPRC maintain Bcl-2 levels, block mitophagy and prevent mitochondria from autophagy degradation. It has been known that overexpression of members of the Bcl-2 family of pro-survival proteins is commonly associated with unfavorable pathogenesis in cancer [44]. Specifically, high levels of Bcl-2 protein are detected in androgen-independent tumors in advanced stages of the pathology [45]. It is well known that most tumor cells need more energy than their normal mature counterparts [46]. Prostate cancer, like other cancers, demonstrates abnormal mitochondria activity [47], [48]. Therefore, patients at late stage of prostate adenocarcinomas exhibit higher levels of LRPPRC than those at early stage of the disease [19].Since LRPPRC-Parkin interaction may play important roles in two seemingly contradicting events of uncontrolled cell growth in cancers and cell death and neuron degeneration in Parkinson's disease, manipulating the interaction provides a new opportunity to target both diseases. Characterization of exact interactive domains in both LRPPRC and Parkin proteins may help to develop drugs to precisely regulate the interaction to differentiate their specific roles from those played by other interactive proteins.
Authors: Alessandra Zanon; Aleksandar Rakovic; Hagen Blankenburg; Nadezhda T Doncheva; Christine Schwienbacher; Alice Serafin; Adrian Alexa; Christian X Weichenberger; Mario Albrecht; Christine Klein; Andrew A Hicks; Peter P Pramstaller; Francisco S Domingues; Irene Pichler Journal: PLoS One Date: 2013-11-11 Impact factor: 3.240
Authors: Jesse S Kerr; Bryan A Adriaanse; Nigel H Greig; Mark P Mattson; M Zameel Cader; Vilhelm A Bohr; Evandro F Fang Journal: Trends Neurosci Date: 2017-02-09 Impact factor: 13.837
Authors: Yahyah Aman; Johannes Frank; Sofie Hindkjær Lautrup; Adrian Matysek; Zhangming Niu; Guang Yang; Liu Shi; Linda H Bergersen; Jon Storm-Mathisen; Lene J Rasmussen; Vilhelm A Bohr; Hilde Nilsen; Evandro F Fang Journal: Mech Ageing Dev Date: 2019-12-05 Impact factor: 5.432
Authors: Daniel J Klionsky; Kotb Abdelmohsen; Akihisa Abe; Md Joynal Abedin; Hagai Abeliovich; Abraham Acevedo Arozena; Hiroaki Adachi; Christopher M Adams; Peter D Adams; Khosrow Adeli; Peter J Adhihetty; Sharon G Adler; Galila Agam; Rajesh Agarwal; Manish K Aghi; Maria Agnello; Patrizia Agostinis; Patricia V Aguilar; Julio Aguirre-Ghiso; Edoardo M Airoldi; Slimane Ait-Si-Ali; Takahiko Akematsu; Emmanuel T Akporiaye; Mohamed Al-Rubeai; Guillermo M Albaiceta; Chris Albanese; Diego Albani; Matthew L Albert; Jesus Aldudo; Hana Algül; Mehrdad Alirezaei; Iraide Alloza; Alexandru Almasan; Maylin Almonte-Beceril; Emad S Alnemri; Covadonga Alonso; Nihal Altan-Bonnet; Dario C Altieri; Silvia Alvarez; Lydia Alvarez-Erviti; Sandro Alves; Giuseppina Amadoro; Atsuo Amano; Consuelo Amantini; Santiago Ambrosio; Ivano Amelio; Amal O Amer; Mohamed Amessou; Angelika Amon; Zhenyi An; Frank A Anania; Stig U Andersen; Usha P Andley; Catherine K Andreadi; Nathalie Andrieu-Abadie; Alberto Anel; David K Ann; Shailendra Anoopkumar-Dukie; Manuela Antonioli; Hiroshi Aoki; Nadezda Apostolova; Saveria Aquila; Katia Aquilano; Koichi Araki; Eli Arama; Agustin Aranda; Jun Araya; Alexandre Arcaro; Esperanza Arias; Hirokazu Arimoto; Aileen R Ariosa; Jane L Armstrong; Thierry Arnould; Ivica Arsov; Katsuhiko Asanuma; Valerie Askanas; Eric Asselin; Ryuichiro Atarashi; Sally S Atherton; Julie D Atkin; Laura D Attardi; Patrick Auberger; Georg Auburger; Laure Aurelian; Riccardo Autelli; Laura Avagliano; Maria Laura Avantaggiati; Limor Avrahami; Suresh Awale; Neelam Azad; Tiziana Bachetti; Jonathan M Backer; Dong-Hun Bae; Jae-Sung Bae; Ok-Nam Bae; Soo Han Bae; Eric H Baehrecke; Seung-Hoon Baek; Stephen Baghdiguian; Agnieszka Bagniewska-Zadworna; Hua Bai; Jie Bai; Xue-Yuan Bai; Yannick Bailly; Kithiganahalli Narayanaswamy Balaji; Walter Balduini; Andrea Ballabio; Rena Balzan; Rajkumar Banerjee; Gábor Bánhegyi; Haijun Bao; Benoit Barbeau; Maria D Barrachina; Esther Barreiro; Bonnie Bartel; Alberto Bartolomé; Diane C Bassham; Maria Teresa Bassi; Robert C Bast; Alakananda Basu; Maria Teresa Batista; Henri Batoko; Maurizio Battino; Kyle Bauckman; Bradley L Baumgarner; K Ulrich Bayer; Rupert Beale; Jean-François Beaulieu; George R Beck; Christoph Becker; J David Beckham; Pierre-André Bédard; Patrick J Bednarski; Thomas J Begley; Christian Behl; Christian Behrends; Georg Mn Behrens; Kevin E Behrns; Eloy Bejarano; Amine Belaid; Francesca Belleudi; Giovanni Bénard; Guy Berchem; Daniele Bergamaschi; Matteo Bergami; Ben Berkhout; Laura Berliocchi; Amélie Bernard; Monique Bernard; Francesca Bernassola; Anne Bertolotti; Amanda S Bess; Sébastien Besteiro; Saverio Bettuzzi; Savita Bhalla; Shalmoli Bhattacharyya; Sujit K Bhutia; Caroline Biagosch; Michele Wolfe Bianchi; Martine Biard-Piechaczyk; Viktor Billes; Claudia Bincoletto; Baris Bingol; Sara W Bird; Marc Bitoun; Ivana Bjedov; Craig Blackstone; Lionel Blanc; Guillermo A Blanco; Heidi Kiil Blomhoff; Emilio Boada-Romero; Stefan Böckler; Marianne Boes; Kathleen Boesze-Battaglia; Lawrence H Boise; Alessandra Bolino; Andrea Boman; Paolo Bonaldo; Matteo Bordi; Jürgen Bosch; Luis M Botana; Joelle Botti; German Bou; Marina Bouché; Marion Bouchecareilh; Marie-Josée Boucher; Michael E Boulton; Sebastien G Bouret; Patricia Boya; Michaël Boyer-Guittaut; Peter V Bozhkov; Nathan Brady; Vania Mm Braga; Claudio Brancolini; Gerhard H Braus; José M Bravo-San Pedro; Lisa A Brennan; Emery H Bresnick; Patrick Brest; Dave Bridges; Marie-Agnès Bringer; Marisa Brini; Glauber C Brito; Bertha Brodin; Paul S Brookes; Eric J Brown; Karen Brown; Hal E Broxmeyer; Alain Bruhat; Patricia Chakur Brum; John H Brumell; Nicola Brunetti-Pierri; Robert J Bryson-Richardson; Shilpa Buch; Alastair M Buchan; Hikmet Budak; Dmitry V Bulavin; Scott J Bultman; Geert Bultynck; Vladimir Bumbasirevic; Yan Burelle; Robert E Burke; Margit Burmeister; Peter Bütikofer; Laura Caberlotto; Ken Cadwell; Monika Cahova; Dongsheng Cai; Jingjing Cai; Qian Cai; Sara Calatayud; Nadine Camougrand; Michelangelo Campanella; Grant R Campbell; Matthew Campbell; Silvia Campello; Robin Candau; Isabella Caniggia; Lavinia Cantoni; Lizhi Cao; Allan B Caplan; Michele Caraglia; Claudio Cardinali; Sandra Morais Cardoso; Jennifer S Carew; Laura A Carleton; Cathleen R Carlin; Silvia Carloni; Sven R Carlsson; Didac Carmona-Gutierrez; Leticia Am Carneiro; Oliana Carnevali; Serena Carra; Alice Carrier; Bernadette Carroll; Caty Casas; Josefina Casas; Giuliana Cassinelli; Perrine Castets; Susana Castro-Obregon; Gabriella Cavallini; Isabella Ceccherini; Francesco Cecconi; Arthur I Cederbaum; Valentín Ceña; Simone Cenci; Claudia Cerella; Davide Cervia; Silvia Cetrullo; Hassan Chaachouay; Han-Jung Chae; Andrei S Chagin; Chee-Yin Chai; Gopal Chakrabarti; Georgios Chamilos; Edmond Yw Chan; Matthew Tv Chan; Dhyan Chandra; Pallavi Chandra; Chih-Peng Chang; Raymond Chuen-Chung Chang; Ta Yuan Chang; John C Chatham; Saurabh Chatterjee; Santosh Chauhan; Yongsheng Che; Michael E Cheetham; Rajkumar Cheluvappa; Chun-Jung Chen; Gang Chen; Guang-Chao Chen; Guoqiang Chen; Hongzhuan Chen; Jeff W Chen; Jian-Kang Chen; Min Chen; Mingzhou Chen; Peiwen Chen; Qi Chen; Quan Chen; Shang-Der Chen; Si Chen; Steve S-L Chen; Wei Chen; Wei-Jung Chen; Wen Qiang Chen; Wenli Chen; Xiangmei Chen; Yau-Hung Chen; Ye-Guang Chen; Yin Chen; Yingyu Chen; Yongshun Chen; Yu-Jen Chen; Yue-Qin Chen; Yujie Chen; Zhen Chen; Zhong Chen; Alan Cheng; Christopher Hk Cheng; Hua Cheng; Heesun Cheong; Sara Cherry; Jason Chesney; Chun Hei Antonio Cheung; Eric Chevet; Hsiang Cheng Chi; Sung-Gil Chi; Fulvio Chiacchiera; Hui-Ling Chiang; Roberto Chiarelli; Mario Chiariello; Marcello Chieppa; Lih-Shen Chin; Mario Chiong; Gigi Nc Chiu; Dong-Hyung Cho; Ssang-Goo Cho; William C Cho; Yong-Yeon Cho; Young-Seok Cho; Augustine Mk Choi; Eui-Ju Choi; Eun-Kyoung Choi; Jayoung Choi; Mary E Choi; Seung-Il Choi; Tsui-Fen Chou; Salem Chouaib; Divaker Choubey; Vinay Choubey; Kuan-Chih Chow; Kamal Chowdhury; Charleen T Chu; Tsung-Hsien Chuang; Taehoon Chun; Hyewon Chung; Taijoon Chung; Yuen-Li Chung; Yong-Joon Chwae; Valentina Cianfanelli; Roberto Ciarcia; Iwona A Ciechomska; Maria Rosa Ciriolo; Mara Cirone; Sofie Claerhout; Michael J Clague; Joan Clària; Peter Gh Clarke; Robert Clarke; Emilio Clementi; Cédric Cleyrat; Miriam Cnop; Eliana M Coccia; Tiziana Cocco; Patrice Codogno; Jörn Coers; Ezra Ew Cohen; David Colecchia; Luisa Coletto; Núria S Coll; Emma Colucci-Guyon; Sergio Comincini; Maria Condello; Katherine L Cook; Graham H Coombs; Cynthia D Cooper; J Mark Cooper; Isabelle Coppens; Maria Tiziana Corasaniti; Marco Corazzari; Ramon Corbalan; Elisabeth Corcelle-Termeau; Mario D Cordero; Cristina Corral-Ramos; Olga Corti; Andrea Cossarizza; Paola Costelli; Safia Costes; Susan L Cotman; Ana Coto-Montes; Sandra Cottet; Eduardo Couve; Lori R Covey; L Ashley Cowart; Jeffery S Cox; Fraser P Coxon; Carolyn B Coyne; Mark S Cragg; Rolf J Craven; Tiziana Crepaldi; Jose L Crespo; Alfredo Criollo; Valeria Crippa; Maria Teresa Cruz; Ana Maria Cuervo; Jose M Cuezva; Taixing Cui; Pedro R Cutillas; Mark J Czaja; Maria F Czyzyk-Krzeska; Ruben K Dagda; Uta Dahmen; Chunsun Dai; Wenjie Dai; Yun Dai; Kevin N Dalby; Luisa Dalla Valle; Guillaume Dalmasso; Marcello D'Amelio; Markus Damme; Arlette Darfeuille-Michaud; Catherine Dargemont; Victor M Darley-Usmar; Srinivasan Dasarathy; Biplab Dasgupta; Srikanta Dash; Crispin R Dass; Hazel Marie Davey; Lester M Davids; David Dávila; Roger J Davis; Ted M Dawson; Valina L Dawson; Paula Daza; Jackie de Belleroche; Paul de Figueiredo; Regina Celia Bressan Queiroz de Figueiredo; José de la Fuente; Luisa De Martino; Antonella De Matteis; Guido Ry De Meyer; Angelo De Milito; Mauro De Santi; Wanderley de Souza; Vincenzo De Tata; Daniela De Zio; Jayanta Debnath; Reinhard Dechant; Jean-Paul Decuypere; Shane Deegan; Benjamin Dehay; Barbara Del Bello; Dominic P Del Re; Régis Delage-Mourroux; Lea Md Delbridge; Louise Deldicque; Elizabeth Delorme-Axford; Yizhen Deng; Joern Dengjel; Melanie Denizot; Paul Dent; Channing J Der; Vojo Deretic; Benoît Derrien; Eric Deutsch; Timothy P Devarenne; Rodney J Devenish; Sabrina Di Bartolomeo; Nicola Di Daniele; Fabio Di Domenico; Alessia Di Nardo; Simone Di Paola; Antonio Di Pietro; Livia Di Renzo; Aaron DiAntonio; Guillermo Díaz-Araya; Ines Díaz-Laviada; Maria T Diaz-Meco; Javier Diaz-Nido; Chad A Dickey; Robert C Dickson; Marc Diederich; Paul Digard; Ivan Dikic; Savithrama P Dinesh-Kumar; Chan Ding; Wen-Xing Ding; Zufeng Ding; Luciana Dini; Jörg Hw Distler; Abhinav Diwan; Mojgan Djavaheri-Mergny; Kostyantyn Dmytruk; Renwick Cj Dobson; Volker Doetsch; Karol Dokladny; Svetlana Dokudovskaya; Massimo Donadelli; X Charlie Dong; Xiaonan Dong; Zheng Dong; Terrence M Donohue; Kelly S Doran; Gabriella D'Orazi; Gerald W Dorn; Victor Dosenko; Sami Dridi; Liat Drucker; Jie Du; Li-Lin Du; Lihuan Du; André du Toit; Priyamvada Dua; Lei Duan; Pu Duann; Vikash Kumar Dubey; Michael R Duchen; Michel A Duchosal; Helene Duez; Isabelle Dugail; Verónica I Dumit; Mara C Duncan; Elaine A Dunlop; William A Dunn; Nicolas Dupont; Luc Dupuis; Raúl V Durán; Thomas M Durcan; Stéphane Duvezin-Caubet; Umamaheswar Duvvuri; Vinay Eapen; Darius Ebrahimi-Fakhari; Arnaud Echard; Leopold Eckhart; Charles L Edelstein; Aimee L Edinger; Ludwig Eichinger; Tobias Eisenberg; Avital Eisenberg-Lerner; N Tony Eissa; Wafik S El-Deiry; Victoria El-Khoury; Zvulun Elazar; Hagit Eldar-Finkelman; Chris Jh Elliott; Enzo Emanuele; Urban Emmenegger; Nikolai Engedal; Anna-Mart Engelbrecht; Simone Engelender; Jorrit M Enserink; Ralf Erdmann; Jekaterina Erenpreisa; Rajaraman Eri; Jason L Eriksen; Andreja Erman; Ricardo Escalante; Eeva-Liisa Eskelinen; Lucile Espert; Lorena Esteban-Martínez; Thomas J Evans; Mario Fabri; Gemma Fabrias; Cinzia Fabrizi; Antonio Facchiano; Nils J Færgeman; Alberto Faggioni; W Douglas Fairlie; Chunhai Fan; Daping Fan; Jie Fan; Shengyun Fang; Manolis Fanto; Alessandro Fanzani; Thomas Farkas; Mathias Faure; Francois B Favier; Howard Fearnhead; Massimo Federici; Erkang Fei; Tania C Felizardo; Hua Feng; Yibin Feng; Yuchen Feng; Thomas A Ferguson; Álvaro F Fernández; Maite G Fernandez-Barrena; Jose C Fernandez-Checa; Arsenio Fernández-López; Martin E Fernandez-Zapico; Olivier Feron; Elisabetta Ferraro; Carmen Veríssima Ferreira-Halder; Laszlo Fesus; Ralph Feuer; Fabienne C Fiesel; Eduardo C Filippi-Chiela; Giuseppe Filomeni; Gian Maria Fimia; John H Fingert; Steven Finkbeiner; Toren Finkel; Filomena Fiorito; Paul B Fisher; Marc Flajolet; Flavio Flamigni; Oliver Florey; Salvatore Florio; R Andres Floto; Marco Folini; Carlo Follo; Edward A Fon; Francesco Fornai; Franco Fortunato; Alessandro Fraldi; Rodrigo Franco; Arnaud Francois; Aurélie François; Lisa B Frankel; Iain Dc Fraser; Norbert Frey; Damien G Freyssenet; Christian Frezza; Scott L Friedman; Daniel E Frigo; Dongxu Fu; José M Fuentes; Juan Fueyo; Yoshio Fujitani; Yuuki Fujiwara; Mikihiro Fujiya; Mitsunori Fukuda; Simone Fulda; Carmela Fusco; Bozena Gabryel; Matthias Gaestel; Philippe Gailly; Malgorzata Gajewska; Sehamuddin Galadari; Gad Galili; Inmaculada Galindo; Maria F Galindo; Giovanna Galliciotti; Lorenzo Galluzzi; Luca Galluzzi; Vincent Galy; Noor Gammoh; Sam Gandy; Anand K Ganesan; Swamynathan Ganesan; Ian G Ganley; Monique Gannagé; Fen-Biao Gao; Feng Gao; Jian-Xin Gao; Lorena García Nannig; Eleonora García Véscovi; Marina Garcia-Macía; Carmen Garcia-Ruiz; Abhishek D Garg; Pramod Kumar Garg; Ricardo Gargini; Nils Christian Gassen; Damián Gatica; Evelina Gatti; Julie Gavard; Evripidis Gavathiotis; Liang Ge; Pengfei Ge; Shengfang Ge; Po-Wu Gean; Vania Gelmetti; Armando A Genazzani; Jiefei Geng; Pascal Genschik; Lisa Gerner; Jason E Gestwicki; David A Gewirtz; Saeid Ghavami; Eric Ghigo; Debabrata Ghosh; Anna Maria Giammarioli; Francesca Giampieri; Claudia Giampietri; Alexandra Giatromanolaki; Derrick J Gibbings; Lara Gibellini; Spencer B Gibson; Vanessa Ginet; Antonio Giordano; Flaviano Giorgini; Elisa Giovannetti; Stephen E Girardin; Suzana Gispert; Sandy Giuliano; Candece L Gladson; Alvaro Glavic; Martin Gleave; Nelly Godefroy; Robert M Gogal; Kuppan Gokulan; Gustavo H Goldman; Delia Goletti; Michael S Goligorsky; Aldrin V Gomes; Ligia C Gomes; Hernando Gomez; Candelaria Gomez-Manzano; Rubén Gómez-Sánchez; Dawit Ap Gonçalves; Ebru Goncu; Qingqiu Gong; Céline Gongora; Carlos B Gonzalez; Pedro Gonzalez-Alegre; Pilar Gonzalez-Cabo; Rosa Ana González-Polo; Ing Swie Goping; Carlos Gorbea; Nikolai V Gorbunov; Daphne R Goring; Adrienne M Gorman; Sharon M Gorski; Sandro Goruppi; Shino Goto-Yamada; Cecilia Gotor; Roberta A Gottlieb; Illana Gozes; Devrim Gozuacik; Yacine Graba; Martin Graef; Giovanna E Granato; Gary Dean Grant; Steven Grant; Giovanni Luca Gravina; Douglas R Green; Alexander Greenhough; Michael T Greenwood; Benedetto Grimaldi; Frédéric Gros; Charles Grose; Jean-Francois Groulx; Florian Gruber; Paolo Grumati; Tilman Grune; Jun-Lin Guan; Kun-Liang Guan; Barbara Guerra; Carlos Guillen; Kailash Gulshan; Jan Gunst; Chuanyong Guo; Lei Guo; Ming Guo; Wenjie Guo; Xu-Guang Guo; Andrea A Gust; Åsa B Gustafsson; Elaine Gutierrez; Maximiliano G Gutierrez; Ho-Shin Gwak; Albert Haas; James E Haber; Shinji Hadano; Monica Hagedorn; David R Hahn; Andrew J Halayko; Anne Hamacher-Brady; Kozo Hamada; Ahmed Hamai; Andrea Hamann; Maho Hamasaki; Isabelle Hamer; Qutayba Hamid; Ester M Hammond; Feng Han; Weidong Han; James T Handa; John A Hanover; Malene Hansen; Masaru Harada; Ljubica Harhaji-Trajkovic; J Wade Harper; Abdel Halim Harrath; Adrian L Harris; James Harris; Udo Hasler; Peter Hasselblatt; Kazuhisa Hasui; Robert G Hawley; Teresa S Hawley; Congcong He; Cynthia Y He; Fengtian He; Gu He; Rong-Rong He; Xian-Hui He; You-Wen He; Yu-Ying He; Joan K Heath; Marie-Josée Hébert; Robert A Heinzen; Gudmundur Vignir Helgason; Michael Hensel; Elizabeth P Henske; Chengtao Her; Paul K Herman; Agustín Hernández; Carlos Hernandez; Sonia Hernández-Tiedra; Claudio Hetz; P Robin Hiesinger; Katsumi Higaki; Sabine Hilfiker; Bradford G Hill; Joseph A Hill; William D Hill; Keisuke Hino; Daniel Hofius; Paul Hofman; Günter U Höglinger; Jörg Höhfeld; Marina K Holz; Yonggeun Hong; David A Hood; Jeroen Jm Hoozemans; Thorsten Hoppe; Chin Hsu; Chin-Yuan Hsu; Li-Chung Hsu; Dong Hu; Guochang Hu; Hong-Ming Hu; Hongbo Hu; Ming Chang Hu; Yu-Chen Hu; Zhuo-Wei Hu; Fang Hua; Ya Hua; Canhua Huang; Huey-Lan Huang; Kuo-How Huang; Kuo-Yang Huang; Shile Huang; Shiqian Huang; Wei-Pang Huang; Yi-Ran Huang; Yong Huang; Yunfei Huang; Tobias B Huber; Patricia Huebbe; Won-Ki Huh; Juha J Hulmi; Gang Min Hur; James H Hurley; Zvenyslava Husak; Sabah Na Hussain; Salik Hussain; Jung Jin Hwang; Seungmin Hwang; Thomas Is Hwang; Atsuhiro Ichihara; Yuzuru Imai; Carol Imbriano; Megumi Inomata; Takeshi Into; Valentina Iovane; Juan L Iovanna; Renato V Iozzo; Nancy Y Ip; Javier E Irazoqui; Pablo Iribarren; Yoshitaka Isaka; Aleksandra J Isakovic; Harry Ischiropoulos; Jeffrey S Isenberg; Mohammad Ishaq; Hiroyuki Ishida; Isao Ishii; Jane E Ishmael; Ciro Isidoro; Ken-Ichi Isobe; Erika Isono; Shohreh Issazadeh-Navikas; Koji Itahana; Eisuke Itakura; Andrei I Ivanov; Anand Krishnan V Iyer; José M Izquierdo; Yotaro Izumi; Valentina Izzo; Marja Jäättelä; Nadia Jaber; Daniel John Jackson; William T Jackson; Tony George Jacob; Thomas S Jacques; Chinnaswamy Jagannath; Ashish Jain; Nihar Ranjan Jana; Byoung Kuk Jang; Alkesh Jani; Bassam Janji; Paulo Roberto Jannig; Patric J Jansson; Steve Jean; Marina Jendrach; Ju-Hong Jeon; Niels Jessen; Eui-Bae Jeung; Kailiang Jia; Lijun Jia; Hong Jiang; Hongchi Jiang; Liwen Jiang; Teng Jiang; Xiaoyan Jiang; Xuejun Jiang; Xuejun Jiang; Ying Jiang; Yongjun Jiang; Alberto Jiménez; Cheng Jin; Hongchuan Jin; Lei Jin; Meiyan Jin; Shengkan Jin; Umesh Kumar Jinwal; Eun-Kyeong Jo; Terje Johansen; Daniel E Johnson; Gail Vw Johnson; James D Johnson; Eric Jonasch; Chris Jones; Leo Ab Joosten; Joaquin Jordan; Anna-Maria Joseph; Bertrand Joseph; Annie M Joubert; Dianwen Ju; Jingfang Ju; Hsueh-Fen Juan; Katrin Juenemann; Gábor Juhász; Hye Seung Jung; Jae U Jung; Yong-Keun Jung; Heinz Jungbluth; Matthew J Justice; Barry Jutten; Nadeem O Kaakoush; Kai Kaarniranta; Allen Kaasik; Tomohiro Kabuta; Bertrand Kaeffer; Katarina Kågedal; Alon Kahana; Shingo Kajimura; Or Kakhlon; Manjula Kalia; Dhan V Kalvakolanu; Yoshiaki Kamada; Konstantinos Kambas; Vitaliy O Kaminskyy; Harm H Kampinga; Mustapha Kandouz; Chanhee Kang; Rui Kang; Tae-Cheon Kang; Tomotake Kanki; Thirumala-Devi Kanneganti; Haruo Kanno; Anumantha G Kanthasamy; Marc Kantorow; Maria Kaparakis-Liaskos; Orsolya Kapuy; Vassiliki Karantza; Md Razaul Karim; Parimal Karmakar; Arthur Kaser; Susmita Kaushik; Thomas Kawula; A Murat Kaynar; Po-Yuan Ke; Zun-Ji Ke; John H Kehrl; Kate E Keller; Jongsook Kim Kemper; Anne K Kenworthy; Oliver Kepp; Andreas Kern; Santosh Kesari; David Kessel; Robin Ketteler; Isis do Carmo Kettelhut; Bilon Khambu; Muzamil Majid Khan; Vinoth Km Khandelwal; Sangeeta Khare; Juliann G Kiang; Amy A Kiger; Akio Kihara; Arianna L Kim; Cheol Hyeon Kim; Deok Ryong Kim; Do-Hyung Kim; Eung Kweon Kim; Hye Young Kim; Hyung-Ryong Kim; Jae-Sung Kim; Jeong Hun Kim; Jin Cheon Kim; Jin Hyoung Kim; Kwang Woon Kim; Michael D Kim; Moon-Moo Kim; Peter K Kim; Seong Who Kim; Soo-Youl Kim; Yong-Sun Kim; Yonghyun Kim; Adi Kimchi; Alec C Kimmelman; Tomonori Kimura; Jason S King; Karla Kirkegaard; Vladimir Kirkin; Lorrie A Kirshenbaum; Shuji Kishi; Yasuo Kitajima; Katsuhiko Kitamoto; Yasushi Kitaoka; Kaio Kitazato; Rudolf A Kley; Walter T Klimecki; Michael Klinkenberg; Jochen Klucken; Helene Knævelsrud; Erwin Knecht; Laura Knuppertz; Jiunn-Liang Ko; Satoru Kobayashi; Jan C Koch; Christelle Koechlin-Ramonatxo; Ulrich Koenig; Young Ho Koh; Katja Köhler; Sepp D Kohlwein; Masato Koike; Masaaki Komatsu; Eiki Kominami; Dexin Kong; Hee Jeong Kong; Eumorphia G Konstantakou; Benjamin T Kopp; Tamas Korcsmaros; Laura Korhonen; Viktor I Korolchuk; Nadya V Koshkina; Yanjun Kou; Michael I Koukourakis; Constantinos Koumenis; Attila L Kovács; Tibor Kovács; Werner J Kovacs; Daisuke Koya; Claudine Kraft; Dimitri Krainc; Helmut Kramer; Tamara Kravic-Stevovic; Wilhelm Krek; Carole Kretz-Remy; Roswitha Krick; Malathi Krishnamurthy; Janos Kriston-Vizi; Guido Kroemer; Michael C Kruer; Rejko Kruger; Nicholas T Ktistakis; Kazuyuki Kuchitsu; Christian Kuhn; Addanki Pratap Kumar; Anuj Kumar; Ashok Kumar; Deepak Kumar; Dhiraj Kumar; Rakesh Kumar; Sharad Kumar; Mondira Kundu; Hsing-Jien Kung; Atsushi Kuno; Sheng-Han Kuo; Jeff Kuret; Tino Kurz; Terry Kwok; Taeg Kyu Kwon; Yong Tae Kwon; Irene Kyrmizi; Albert R La Spada; Frank Lafont; Tim Lahm; Aparna Lakkaraju; Truong Lam; Trond Lamark; Steve Lancel; Terry H Landowski; Darius J R Lane; Jon D Lane; Cinzia Lanzi; Pierre Lapaquette; Louis R Lapierre; Jocelyn Laporte; Johanna Laukkarinen; Gordon W Laurie; Sergio Lavandero; Lena Lavie; Matthew J LaVoie; Betty Yuen Kwan Law; Helen Ka-Wai Law; Kelsey B Law; Robert Layfield; Pedro A Lazo; Laurent Le Cam; Karine G Le Roch; Hervé Le Stunff; Vijittra Leardkamolkarn; Marc Lecuit; Byung-Hoon Lee; Che-Hsin Lee; Erinna F Lee; Gyun Min Lee; He-Jin Lee; Hsinyu Lee; Jae Keun Lee; Jongdae Lee; Ju-Hyun Lee; Jun Hee Lee; Michael Lee; Myung-Shik Lee; Patty J Lee; Sam W Lee; Seung-Jae Lee; Shiow-Ju Lee; Stella Y Lee; Sug Hyung Lee; Sung Sik Lee; Sung-Joon Lee; Sunhee Lee; Ying-Ray Lee; Yong J Lee; Young H Lee; Christiaan Leeuwenburgh; Sylvain Lefort; Renaud Legouis; Jinzhi Lei; Qun-Ying Lei; David A Leib; Gil Leibowitz; Istvan Lekli; Stéphane D Lemaire; John J Lemasters; Marius K Lemberg; Antoinette Lemoine; Shuilong Leng; Guido Lenz; Paola Lenzi; Lilach O Lerman; Daniele Lettieri Barbato; Julia I-Ju Leu; Hing Y Leung; Beth Levine; Patrick A Lewis; Frank Lezoualc'h; Chi Li; Faqiang Li; Feng-Jun Li; Jun Li; Ke Li; Lian Li; Min Li; Min Li; Qiang Li; Rui Li; Sheng Li; Wei Li; Wei Li; Xiaotao Li; Yumin Li; Jiqin Lian; Chengyu Liang; Qiangrong Liang; Yulin Liao; Joana Liberal; Pawel P Liberski; Pearl Lie; Andrew P Lieberman; Hyunjung Jade Lim; Kah-Leong Lim; Kyu Lim; Raquel T Lima; Chang-Shen Lin; Chiou-Feng Lin; Fang Lin; Fangming Lin; Fu-Cheng Lin; Kui Lin; Kwang-Huei Lin; Pei-Hui Lin; Tianwei Lin; Wan-Wan Lin; Yee-Shin Lin; Yong Lin; Rafael Linden; Dan Lindholm; Lisa M Lindqvist; Paul Lingor; Andreas Linkermann; Lance A Liotta; Marta M Lipinski; Vitor A Lira; Michael P Lisanti; Paloma B Liton; Bo Liu; Chong Liu; Chun-Feng Liu; Fei Liu; Hung-Jen Liu; Jianxun Liu; Jing-Jing Liu; Jing-Lan Liu; Ke Liu; Leyuan Liu; Liang Liu; Quentin Liu; Rong-Yu Liu; Shiming Liu; Shuwen Liu; Wei Liu; Xian-De Liu; Xiangguo Liu; Xiao-Hong Liu; Xinfeng Liu; Xu Liu; Xueqin Liu; Yang Liu; Yule Liu; Zexian Liu; Zhe Liu; Juan P Liuzzi; Gérard Lizard; Mila Ljujic; Irfan J Lodhi; Susan E Logue; Bal L Lokeshwar; Yun Chau Long; Sagar Lonial; Benjamin Loos; Carlos López-Otín; Cristina López-Vicario; Mar Lorente; Philip L Lorenzi; Péter Lõrincz; Marek Los; Michael T Lotze; Penny E Lovat; Binfeng Lu; Bo Lu; Jiahong Lu; Qing Lu; She-Min Lu; Shuyan Lu; Yingying Lu; Frédéric Luciano; Shirley Luckhart; John Milton Lucocq; Paula Ludovico; Aurelia Lugea; Nicholas W Lukacs; Julian J Lum; Anders H Lund; Honglin Luo; Jia Luo; Shouqing Luo; Claudio Luparello; Timothy Lyons; Jianjie Ma; Yi Ma; Yong Ma; Zhenyi Ma; Juliano Machado; Glaucia M Machado-Santelli; Fernando Macian; Gustavo C MacIntosh; Jeffrey P MacKeigan; Kay F Macleod; John D MacMicking; Lee Ann MacMillan-Crow; Frank Madeo; Muniswamy Madesh; Julio Madrigal-Matute; Akiko Maeda; Tatsuya Maeda; Gustavo Maegawa; Emilia Maellaro; Hannelore Maes; Marta Magariños; Kenneth Maiese; Tapas K Maiti; Luigi Maiuri; Maria Chiara Maiuri; Carl G Maki; Roland Malli; Walter Malorni; Alina Maloyan; Fathia Mami-Chouaib; Na Man; Joseph D Mancias; Eva-Maria Mandelkow; Michael A Mandell; Angelo A Manfredi; Serge N Manié; Claudia Manzoni; Kai Mao; Zixu Mao; Zong-Wan Mao; Philippe Marambaud; Anna Maria Marconi; Zvonimir Marelja; Gabriella Marfe; Marta Margeta; Eva Margittai; Muriel Mari; Francesca V Mariani; Concepcio Marin; Sara Marinelli; Guillermo Mariño; Ivanka Markovic; Rebecca Marquez; Alberto M Martelli; Sascha Martens; Katie R Martin; Seamus J Martin; Shaun Martin; Miguel A Martin-Acebes; Paloma Martín-Sanz; Camille Martinand-Mari; Wim Martinet; Jennifer Martinez; Nuria Martinez-Lopez; Ubaldo Martinez-Outschoorn; Moisés Martínez-Velázquez; Marta Martinez-Vicente; Waleska Kerllen Martins; Hirosato Mashima; James A Mastrianni; Giuseppe Matarese; Paola Matarrese; Roberto Mateo; Satoaki Matoba; Naomichi Matsumoto; Takehiko Matsushita; Akira Matsuura; Takeshi Matsuzawa; Mark P Mattson; Soledad Matus; Norma Maugeri; Caroline Mauvezin; Andreas Mayer; Dusica Maysinger; Guillermo D Mazzolini; Mary Kate McBrayer; Kimberly McCall; Craig McCormick; Gerald M McInerney; Skye C McIver; Sharon McKenna; John J McMahon; Iain A McNeish; Fatima Mechta-Grigoriou; Jan Paul Medema; Diego L Medina; Klara Megyeri; Maryam Mehrpour; Jawahar L Mehta; Yide Mei; Ute-Christiane Meier; Alfred J Meijer; Alicia Meléndez; Gerry Melino; Sonia Melino; Edesio Jose Tenorio de Melo; Maria A Mena; Marc D Meneghini; Javier A Menendez; Regina Menezes; Liesu Meng; Ling-Hua Meng; Songshu Meng; Rossella Menghini; A Sue Menko; Rubem Fs Menna-Barreto; Manoj B Menon; Marco A Meraz-Ríos; Giuseppe Merla; Luciano Merlini; Angelica M Merlot; Andreas Meryk; Stefania Meschini; Joel N Meyer; Man-Tian Mi; Chao-Yu Miao; Lucia Micale; Simon Michaeli; Carine Michiels; Anna Rita Migliaccio; Anastasia Susie Mihailidou; Dalibor Mijaljica; Katsuhiko Mikoshiba; Enrico Milan; Leonor Miller-Fleming; Gordon B Mills; Ian G Mills; Georgia Minakaki; Berge A Minassian; Xiu-Fen Ming; Farida Minibayeva; Elena A Minina; Justine D Mintern; Saverio Minucci; Antonio Miranda-Vizuete; Claire H Mitchell; Shigeki Miyamoto; Keisuke Miyazawa; Noboru Mizushima; Katarzyna Mnich; Baharia Mograbi; Simin Mohseni; Luis Ferreira Moita; Marco Molinari; Maurizio Molinari; Andreas Buch Møller; Bertrand Mollereau; Faustino Mollinedo; Marco Mongillo; Martha M Monick; Serena Montagnaro; Craig Montell; Darren J Moore; Michael N Moore; Rodrigo Mora-Rodriguez; Paula I Moreira; Etienne Morel; Maria Beatrice Morelli; Sandra Moreno; Michael J Morgan; Arnaud Moris; Yuji Moriyasu; Janna L Morrison; Lynda A Morrison; Eugenia Morselli; Jorge Moscat; Pope L Moseley; Serge Mostowy; Elisa Motori; Denis Mottet; Jeremy C Mottram; Charbel E-H Moussa; Vassiliki E Mpakou; Hasan Mukhtar; Jean M Mulcahy Levy; Sylviane Muller; Raquel Muñoz-Moreno; Cristina Muñoz-Pinedo; Christian Münz; Maureen E Murphy; James T Murray; Aditya Murthy; Indira U Mysorekar; Ivan R Nabi; Massimo Nabissi; Gustavo A Nader; Yukitoshi Nagahara; Yoshitaka Nagai; Kazuhiro Nagata; Anika Nagelkerke; Péter Nagy; Samisubbu R Naidu; Sreejayan Nair; Hiroyasu Nakano; Hitoshi Nakatogawa; Meera Nanjundan; Gennaro Napolitano; Naweed I Naqvi; Roberta Nardacci; Derek P Narendra; Masashi Narita; Anna Chiara Nascimbeni; Ramesh Natarajan; Luiz C Navegantes; Steffan T Nawrocki; Taras Y Nazarko; Volodymyr Y Nazarko; Thomas Neill; Luca M Neri; Mihai G Netea; Romana T Netea-Maier; Bruno M Neves; Paul A Ney; Ioannis P Nezis; Hang Tt Nguyen; Huu Phuc Nguyen; Anne-Sophie Nicot; Hilde Nilsen; Per Nilsson; Mikio Nishimura; Ichizo Nishino; Mireia Niso-Santano; Hua Niu; Ralph A Nixon; Vincent Co Njar; Takeshi Noda; Angelika A Noegel; Elsie Magdalena Nolte; Erik Norberg; Koenraad K Norga; Sakineh Kazemi Noureini; Shoji Notomi; Lucia Notterpek; Karin Nowikovsky; Nobuyuki Nukina; Thorsten Nürnberger; Valerie B O'Donnell; Tracey O'Donovan; Peter J O'Dwyer; Ina Oehme; Clara L Oeste; Michinaga Ogawa; Besim Ogretmen; Yuji Ogura; Young J Oh; Masaki Ohmuraya; Takayuki Ohshima; Rani Ojha; Koji Okamoto; Toshiro Okazaki; F Javier Oliver; Karin Ollinger; Stefan Olsson; Daniel P Orban; Paulina Ordonez; Idil Orhon; Laszlo Orosz; Eyleen J O'Rourke; Helena Orozco; Angel L Ortega; Elena Ortona; Laura D Osellame; Junko Oshima; Shigeru Oshima; Heinz D Osiewacz; Takanobu Otomo; Kinya Otsu; Jing-Hsiung James Ou; Tiago F Outeiro; Dong-Yun Ouyang; Hongjiao Ouyang; Michael Overholtzer; Michelle A Ozbun; P Hande Ozdinler; Bulent Ozpolat; Consiglia Pacelli; Paolo Paganetti; Guylène Page; Gilles Pages; Ugo Pagnini; Beata Pajak; Stephen C Pak; Karolina Pakos-Zebrucka; Nazzy Pakpour; Zdena Palková; Francesca Palladino; Kathrin Pallauf; Nicolas Pallet; Marta Palmieri; Søren R Paludan; Camilla Palumbo; Silvia Palumbo; Olatz Pampliega; Hongming Pan; Wei Pan; Theocharis Panaretakis; Aseem Pandey; Areti Pantazopoulou; Zuzana Papackova; Daniela L Papademetrio; Issidora Papassideri; Alessio Papini; Nirmala Parajuli; Julian Pardo; Vrajesh V Parekh; Giancarlo Parenti; Jong-In Park; Junsoo Park; Ohkmae K Park; Roy Parker; Rosanna Parlato; Jan B Parys; Katherine R Parzych; Jean-Max Pasquet; Benoit Pasquier; Kishore Bs Pasumarthi; Daniel Patschan; Cam Patterson; Sophie Pattingre; Scott Pattison; Arnim Pause; Hermann Pavenstädt; Flaminia Pavone; Zully Pedrozo; Fernando J Peña; Miguel A Peñalva; Mario Pende; Jianxin Peng; Fabio Penna; Josef M Penninger; Anna Pensalfini; Salvatore Pepe; Gustavo Js Pereira; Paulo C Pereira; Verónica Pérez-de la Cruz; María Esther Pérez-Pérez; Diego Pérez-Rodríguez; Dolores Pérez-Sala; Celine Perier; Andras Perl; David H Perlmutter; Ida Perrotta; Shazib Pervaiz; Maija Pesonen; Jeffrey E Pessin; Godefridus J Peters; Morten Petersen; Irina Petrache; Basil J Petrof; Goran Petrovski; James M Phang; Mauro Piacentini; Marina Pierdominici; Philippe Pierre; Valérie Pierrefite-Carle; Federico Pietrocola; Felipe X Pimentel-Muiños; Mario Pinar; Benjamin Pineda; Ronit Pinkas-Kramarski; Marcello Pinti; Paolo Pinton; Bilal Piperdi; James M Piret; Leonidas C Platanias; Harald W Platta; Edward D Plowey; Stefanie Pöggeler; Marc Poirot; Peter Polčic; Angelo Poletti; Audrey H Poon; Hana Popelka; Blagovesta Popova; Izabela Poprawa; Shibu M Poulose; Joanna Poulton; Scott K Powers; Ted Powers; Mercedes Pozuelo-Rubio; Krisna Prak; Reinhild Prange; Mark Prescott; Muriel Priault; Sharon Prince; Richard L Proia; Tassula Proikas-Cezanne; Holger Prokisch; Vasilis J Promponas; Karin Przyklenk; Rosa Puertollano; Subbiah Pugazhenthi; Luigi Puglielli; Aurora Pujol; Julien Puyal; Dohun Pyeon; Xin Qi; Wen-Bin Qian; Zheng-Hong Qin; Yu Qiu; Ziwei Qu; Joe Quadrilatero; Frederick Quinn; Nina Raben; Hannah Rabinowich; Flavia Radogna; Michael J Ragusa; Mohamed Rahmani; Komal Raina; Sasanka Ramanadham; Rajagopal Ramesh; Abdelhaq Rami; Sarron Randall-Demllo; Felix Randow; Hai Rao; V Ashutosh Rao; Blake B Rasmussen; Tobias M Rasse; Edward A Ratovitski; Pierre-Emmanuel Rautou; Swapan K Ray; Babak Razani; Bruce H Reed; Fulvio Reggiori; Markus Rehm; Andreas S Reichert; Theo Rein; David J Reiner; Eric Reits; Jun Ren; Xingcong Ren; Maurizio Renna; Jane Eb Reusch; Jose L Revuelta; Leticia Reyes; Alireza R Rezaie; Robert I Richards; Des R Richardson; Clémence Richetta; Michael A Riehle; Bertrand H Rihn; Yasuko Rikihisa; Brigit E Riley; Gerald Rimbach; Maria Rita Rippo; Konstantinos Ritis; Federica Rizzi; Elizete Rizzo; Peter J Roach; Jeffrey Robbins; Michel Roberge; Gabriela Roca; Maria Carmela Roccheri; Sonia Rocha; Cecilia Mp Rodrigues; Clara I Rodríguez; Santiago Rodriguez de Cordoba; Natalia Rodriguez-Muela; Jeroen Roelofs; Vladimir V Rogov; Troy T Rohn; Bärbel Rohrer; Davide Romanelli; Luigina Romani; Patricia Silvia Romano; M Isabel G Roncero; Jose Luis Rosa; Alicia Rosello; Kirill V Rosen; Philip Rosenstiel; Magdalena Rost-Roszkowska; Kevin A Roth; Gael Roué; Mustapha Rouis; Kasper M Rouschop; Daniel T Ruan; Diego Ruano; David C Rubinsztein; Edmund B Rucker; Assaf Rudich; Emil Rudolf; Ruediger Rudolf; Markus A Ruegg; Carmen Ruiz-Roldan; Avnika Ashok Ruparelia; Paola Rusmini; David W Russ; Gian Luigi Russo; Giuseppe Russo; Rossella Russo; Tor Erik Rusten; Victoria Ryabovol; Kevin M Ryan; Stefan W Ryter; David M Sabatini; Michael Sacher; Carsten Sachse; Michael N Sack; Junichi Sadoshima; Paul Saftig; Ronit Sagi-Eisenberg; Sumit Sahni; Pothana Saikumar; Tsunenori Saito; Tatsuya Saitoh; Koichi Sakakura; Machiko Sakoh-Nakatogawa; Yasuhito Sakuraba; María Salazar-Roa; Paolo Salomoni; Ashok K Saluja; Paul M Salvaterra; Rosa Salvioli; Afshin Samali; Anthony Mj Sanchez; José A Sánchez-Alcázar; Ricardo Sanchez-Prieto; Marco Sandri; Miguel A Sanjuan; Stefano Santaguida; Laura Santambrogio; Giorgio Santoni; Claudia Nunes Dos Santos; Shweta Saran; Marco Sardiello; Graeme Sargent; Pallabi Sarkar; Sovan Sarkar; Maria Rosa Sarrias; Minnie M Sarwal; Chihiro Sasakawa; Motoko Sasaki; Miklos Sass; Ken Sato; Miyuki Sato; Joseph Satriano; Niramol Savaraj; Svetlana Saveljeva; Liliana Schaefer; Ulrich E Schaible; Michael Scharl; Hermann M Schatzl; Randy Schekman; Wiep Scheper; Alfonso Schiavi; Hyman M Schipper; Hana Schmeisser; Jens Schmidt; Ingo Schmitz; Bianca E Schneider; E Marion Schneider; Jaime L Schneider; Eric A Schon; Miriam J Schönenberger; Axel H Schönthal; Daniel F Schorderet; Bernd Schröder; Sebastian Schuck; Ryan J Schulze; Melanie Schwarten; Thomas L Schwarz; Sebastiano Sciarretta; Kathleen Scotto; A Ivana Scovassi; Robert A Screaton; Mark Screen; Hugo Seca; Simon Sedej; Laura Segatori; Nava Segev; Per O Seglen; Jose M Seguí-Simarro; Juan Segura-Aguilar; Ekihiro Seki; Christian Sell; Iban Seiliez; Clay F Semenkovich; Gregg L Semenza; Utpal Sen; Andreas L Serra; Ana Serrano-Puebla; Hiromi Sesaki; Takao Setoguchi; Carmine Settembre; John J Shacka; Ayesha N Shajahan-Haq; Irving M Shapiro; Shweta Sharma; Hua She; C-K James Shen; Chiung-Chyi Shen; Han-Ming Shen; Sanbing Shen; Weili Shen; Rui Sheng; Xianyong Sheng; Zu-Hang Sheng; Trevor G Shepherd; Junyan Shi; Qiang Shi; Qinghua Shi; Yuguang Shi; Shusaku Shibutani; Kenichi Shibuya; Yoshihiro Shidoji; Jeng-Jer Shieh; Chwen-Ming Shih; Yohta Shimada; Shigeomi Shimizu; Dong Wook Shin; Mari L Shinohara; Michiko Shintani; Takahiro Shintani; Tetsuo Shioi; Ken Shirabe; Ronit Shiri-Sverdlov; Orian Shirihai; Gordon C Shore; Chih-Wen Shu; Deepak Shukla; Andriy A Sibirny; Valentina Sica; Christina J Sigurdson; Einar M Sigurdsson; Puran Singh Sijwali; Beata Sikorska; Wilian A Silveira; Sandrine Silvente-Poirot; Gary A Silverman; Jan Simak; Thomas Simmet; Anna Katharina Simon; Hans-Uwe Simon; Cristiano Simone; Matias Simons; Anne Simonsen; Rajat Singh; Shivendra V Singh; Shrawan K Singh; Debasish Sinha; Sangita Sinha; Frank A Sinicrope; Agnieszka Sirko; Kapil Sirohi; Balindiwe Jn Sishi; Annie Sittler; Parco M Siu; Efthimios Sivridis; Anna Skwarska; Ruth Slack; Iva Slaninová; Nikolai Slavov; Soraya S Smaili; Keiran Sm Smalley; Duncan R Smith; Stefaan J Soenen; Scott A Soleimanpour; Anita Solhaug; Kumaravel Somasundaram; Jin H Son; Avinash Sonawane; Chunjuan Song; Fuyong Song; Hyun Kyu Song; Ju-Xian Song; Wei Song; Kai Y Soo; Anil K Sood; Tuck Wah Soong; Virawudh Soontornniyomkij; Maurizio Sorice; Federica Sotgia; David R Soto-Pantoja; Areechun Sotthibundhu; Maria João Sousa; Herman P Spaink; Paul N Span; Anne Spang; Janet D Sparks; Peter G Speck; Stephen A Spector; Claudia D Spies; Wolfdieter Springer; Daret St Clair; Alessandra Stacchiotti; Bart Staels; Michael T Stang; Daniel T Starczynowski; Petro Starokadomskyy; Clemens Steegborn; John W Steele; Leonidas Stefanis; Joan Steffan; Christine M Stellrecht; Harald Stenmark; Tomasz M Stepkowski; Stęphan T Stern; Craig Stevens; Brent R Stockwell; Veronika Stoka; Zuzana Storchova; Björn Stork; Vassilis Stratoulias; Dimitrios J Stravopodis; Pavel Strnad; Anne Marie Strohecker; Anna-Lena Ström; Per Stromhaug; Jiri Stulik; Yu-Xiong Su; Zhaoliang Su; Carlos S Subauste; Srinivasa Subramaniam; Carolyn M Sue; Sang Won Suh; Xinbing Sui; Supawadee Sukseree; David Sulzer; Fang-Lin Sun; Jiaren Sun; Jun Sun; Shi-Yong Sun; Yang Sun; Yi Sun; Yingjie Sun; Vinod Sundaramoorthy; Joseph Sung; Hidekazu Suzuki; Kuninori Suzuki; Naoki Suzuki; Tadashi Suzuki; Yuichiro J Suzuki; Michele S Swanson; Charles Swanton; Karl Swärd; Ghanshyam Swarup; Sean T Sweeney; Paul W Sylvester; Zsuzsanna Szatmari; Eva Szegezdi; Peter W Szlosarek; Heinrich Taegtmeyer; Marco Tafani; Emmanuel Taillebourg; Stephen Wg Tait; Krisztina Takacs-Vellai; Yoshinori Takahashi; Szabolcs Takáts; Genzou Takemura; Nagio Takigawa; Nicholas J Talbot; Elena Tamagno; Jerome Tamburini; Cai-Ping Tan; Lan Tan; Mei Lan Tan; Ming Tan; Yee-Joo Tan; Keiji Tanaka; Masaki Tanaka; Daolin Tang; Dingzhong Tang; Guomei Tang; Isei Tanida; Kunikazu Tanji; Bakhos A Tannous; Jose A Tapia; Inmaculada Tasset-Cuevas; Marc Tatar; Iman Tavassoly; Nektarios Tavernarakis; Allen Taylor; Graham S Taylor; Gregory A Taylor; J Paul Taylor; Mark J Taylor; Elena V Tchetina; Andrew R Tee; Fatima Teixeira-Clerc; Sucheta Telang; Tewin Tencomnao; Ba-Bie Teng; Ru-Jeng Teng; Faraj Terro; Gianluca Tettamanti; Arianne L Theiss; Anne E Theron; Kelly Jean Thomas; Marcos P Thomé; Paul G Thomes; Andrew Thorburn; Jeremy Thorner; Thomas Thum; Michael Thumm; Teresa Lm Thurston; Ling Tian; Andreas Till; Jenny Pan-Yun Ting; Vladimir I Titorenko; Lilach Toker; Stefano Toldo; Sharon A Tooze; Ivan Topisirovic; Maria Lyngaas Torgersen; Liliana Torosantucci; Alicia Torriglia; Maria Rosaria Torrisi; Cathy Tournier; Roberto Towns; Vladimir Trajkovic; Leonardo H Travassos; Gemma Triola; Durga Nand Tripathi; Daniela Trisciuoglio; Rodrigo Troncoso; Ioannis P Trougakos; Anita C Truttmann; Kuen-Jer Tsai; Mario P Tschan; Yi-Hsin Tseng; Takayuki Tsukuba; Allan Tsung; Andrey S Tsvetkov; Shuiping Tu; Hsing-Yu Tuan; Marco Tucci; David A Tumbarello; Boris Turk; Vito Turk; Robin Fb Turner; Anders A Tveita; Suresh C Tyagi; Makoto Ubukata; Yasuo Uchiyama; Andrej Udelnow; Takashi Ueno; Midori Umekawa; Rika Umemiya-Shirafuji; Benjamin R Underwood; Christian Ungermann; Rodrigo P Ureshino; Ryo Ushioda; Vladimir N Uversky; Néstor L Uzcátegui; Thomas Vaccari; Maria I Vaccaro; Libuše Váchová; Helin Vakifahmetoglu-Norberg; Rut Valdor; Enza Maria Valente; Francois Vallette; Angela M Valverde; Greet Van den Berghe; Ludo Van Den Bosch; Gijs R van den Brink; F Gisou van der Goot; Ida J van der Klei; Luc Jw van der Laan; Wouter G van Doorn; Marjolein van Egmond; Kenneth L van Golen; Luc Van Kaer; Menno van Lookeren Campagne; Peter Vandenabeele; Wim Vandenberghe; Ilse Vanhorebeek; Isabel Varela-Nieto; M Helena Vasconcelos; Radovan Vasko; Demetrios G Vavvas; Ignacio Vega-Naredo; Guillermo Velasco; Athanassios D Velentzas; Panagiotis D Velentzas; Tibor Vellai; Edo Vellenga; Mikkel Holm Vendelbo; Kartik Venkatachalam; Natascia Ventura; Salvador Ventura; Patrícia St Veras; Mireille Verdier; Beata G Vertessy; Andrea Viale; Michel Vidal; Helena L A Vieira; Richard D Vierstra; Nadarajah Vigneswaran; Neeraj Vij; Miquel Vila; Margarita Villar; Victor H Villar; Joan Villarroya; Cécile Vindis; Giampietro Viola; Maria Teresa Viscomi; Giovanni Vitale; Dan T Vogl; Olga V Voitsekhovskaja; Clarissa von Haefen; Karin von Schwarzenberg; Daniel E Voth; Valérie Vouret-Craviari; Kristina Vuori; Jatin M Vyas; Christian Waeber; Cheryl Lyn Walker; Mark J Walker; Jochen Walter; Lei Wan; Xiangbo Wan; Bo Wang; Caihong Wang; Chao-Yung Wang; Chengshu Wang; Chenran Wang; Chuangui Wang; Dong Wang; Fen Wang; Fuxin Wang; Guanghui Wang; Hai-Jie Wang; Haichao Wang; Hong-Gang Wang; Hongmin Wang; Horng-Dar Wang; Jing Wang; Junjun Wang; Mei Wang; Mei-Qing Wang; Pei-Yu Wang; Peng Wang; Richard C Wang; Shuo Wang; Ting-Fang Wang; Xian Wang; Xiao-Jia Wang; Xiao-Wei Wang; Xin Wang; Xuejun Wang; Yan Wang; Yanming Wang; Ying Wang; Ying-Jan Wang; Yipeng Wang; Yu Wang; Yu Tian Wang; Yuqing Wang; Zhi-Nong Wang; Pablo Wappner; Carl Ward; Diane McVey Ward; Gary Warnes; Hirotaka Watada; Yoshihisa Watanabe; Kei Watase; Timothy E Weaver; Colin D Weekes; Jiwu Wei; Thomas Weide; Conrad C Weihl; Günther Weindl; Simone Nardin Weis; Longping Wen; Xin Wen; Yunfei Wen; Benedikt Westermann; Cornelia M Weyand; Anthony R White; Eileen White; J Lindsay Whitton; Alexander J Whitworth; Joëlle Wiels; Franziska Wild; Manon E Wildenberg; Tom Wileman; Deepti Srinivas Wilkinson; Simon Wilkinson; Dieter Willbold; Chris Williams; Katherine Williams; Peter R Williamson; Konstanze F Winklhofer; Steven S Witkin; Stephanie E Wohlgemuth; Thomas Wollert; Ernst J Wolvetang; Esther Wong; G William Wong; Richard W Wong; Vincent Kam Wai Wong; Elizabeth A Woodcock; Karen L Wright; Chunlai Wu; Defeng Wu; Gen Sheng Wu; Jian Wu; Junfang Wu; Mian Wu; Min Wu; Shengzhou Wu; William Kk Wu; Yaohua Wu; Zhenlong Wu; Cristina Pr Xavier; Ramnik J Xavier; Gui-Xian Xia; Tian Xia; Weiliang Xia; Yong Xia; Hengyi Xiao; Jian Xiao; Shi Xiao; Wuhan Xiao; Chuan-Ming Xie; Zhiping Xie; Zhonglin Xie; Maria Xilouri; Yuyan Xiong; Chuanshan Xu; Congfeng Xu; Feng Xu; Haoxing Xu; Hongwei Xu; Jian Xu; Jianzhen Xu; Jinxian Xu; Liang Xu; Xiaolei Xu; Yangqing Xu; Ye Xu; Zhi-Xiang Xu; Ziheng Xu; Yu Xue; Takahiro Yamada; Ai Yamamoto; Koji Yamanaka; Shunhei Yamashina; Shigeko Yamashiro; Bing Yan; Bo Yan; Xianghua Yan; Zhen Yan; Yasuo Yanagi; Dun-Sheng Yang; Jin-Ming Yang; Liu Yang; Minghua Yang; Pei-Ming Yang; Peixin Yang; Qian Yang; Wannian Yang; Wei Yuan Yang; Xuesong Yang; Yi Yang; Ying Yang; Zhifen Yang; Zhihong Yang; Meng-Chao Yao; Pamela J Yao; Xiaofeng Yao; Zhenyu Yao; Zhiyuan Yao; Linda S Yasui; Mingxiang Ye; Barry Yedvobnick; Behzad Yeganeh; Elizabeth S Yeh; Patricia L Yeyati; Fan Yi; Long Yi; Xiao-Ming Yin; Calvin K Yip; Yeong-Min Yoo; Young Hyun Yoo; Seung-Yong Yoon; Ken-Ichi Yoshida; Tamotsu Yoshimori; Ken H Young; Huixin Yu; Jane J Yu; Jin-Tai Yu; Jun Yu; Li Yu; W Haung Yu; Xiao-Fang Yu; Zhengping Yu; Junying Yuan; Zhi-Min Yuan; Beatrice Yjt Yue; Jianbo Yue; Zhenyu Yue; David N Zacks; Eldad Zacksenhaus; Nadia Zaffaroni; Tania Zaglia; Zahra Zakeri; Vincent Zecchini; Jinsheng Zeng; Min Zeng; Qi Zeng; Antonis S Zervos; Donna D Zhang; Fan Zhang; Guo Zhang; Guo-Chang Zhang; Hao Zhang; Hong Zhang; Hong Zhang; Hongbing Zhang; Jian Zhang; Jian Zhang; Jiangwei Zhang; Jianhua Zhang; Jing-Pu Zhang; Li Zhang; Lin Zhang; Lin Zhang; Long Zhang; Ming-Yong Zhang; Xiangnan Zhang; Xu Dong Zhang; Yan Zhang; Yang Zhang; Yanjin Zhang; Yingmei Zhang; Yunjiao Zhang; Mei Zhao; Wei-Li Zhao; Xiaonan Zhao; Yan G Zhao; Ying Zhao; Yongchao Zhao; Yu-Xia Zhao; Zhendong Zhao; Zhizhuang J Zhao; Dexian Zheng; Xi-Long Zheng; Xiaoxiang Zheng; Boris Zhivotovsky; Qing Zhong; Guang-Zhou Zhou; Guofei Zhou; Huiping Zhou; Shu-Feng Zhou; Xu-Jie Zhou; Hongxin Zhu; Hua Zhu; Wei-Guo Zhu; Wenhua Zhu; Xiao-Feng Zhu; Yuhua Zhu; Shi-Mei Zhuang; Xiaohong Zhuang; Elio Ziparo; Christos E Zois; Teresa Zoladek; Wei-Xing Zong; Antonio Zorzano; Susu M Zughaier Journal: Autophagy Date: 2016 Impact factor: 16.016